Automated injector device for drug delivery

Abstract

An automatic injector device for delivering a medication is disclosed. The automatic injector device includes a syringe assembly having a needle adapted to expel the medication from the syringe assembly and a barrel adapted to hold the medication. The syringe assembly includes a plunger positioned coaxially with the barrel and adapted to reciprocate within the barrel to expel the medication from the barrel. The syringe assembly further includes a locking member adapted to engage with the plunger and hold the plunger in a certain position relative to the barrel. The position of the plunger relative to the barrel is adjustable to vary the amount of medication expelled from the barrel. The position of the plunger is adjusted by engaging the locking member with the plunger at one of multiple positions along the length of the plunger.

Description

Technical Field

[0001] The present disclosure relates to drug delivery devices, more specifically, to automatic injector devices for delivering drugs.

Background Art

[0002] With the progress of technology, various injection devices such as manual injection devices and automatic injector devices are being adopted to administer drugs for applications such as medical treatment, therapy, diagnosis, pharmaceuticals, cosmetics, etc. Today, users and medical professionals are increasingly inclined to use automatic injector devices to administer drugs. One significant reason for this trend is that the amount of training required to use automatic injector devices is significantly reduced.

[0003] Generally, an automatic injector device includes a pre-filled syringe or cartridge filled with a specific amount of drug to be delivered to the user. The amount of drug filled in the automatic injector device depends on various parameters such as the type of drug and the user's medical condition. Currently, an automatic injector device can only be configured to carry a specific amount of drug and cannot provide a preparation for changing the amount of drug without changing the structural or operational characteristics of various sub-components of the automatic injector device.

[0004] Therefore, this may significantly reduce the overall reusability of automatic injector devices for administering different types and dosages of drugs. Furthermore, the type and dosage of the drug to be administered may act as design constraints on the manufacture of automatic injector devices. For example, the sub-components of an automatic injector device need to be manufactured based on the type of drug and the corresponding dosage of such drug administered through the automatic injector device. This may significantly increase the overall manufacturing cost of the automatic injector device. [Overview of the Initiative]

[0005] This summary is provided to introduce, in a simplified form, a selection of concepts that will be further described in the detailed description of the invention. This summary is not intended to identify any important or essential inventive concepts of the invention, nor is it intended to determine the scope of the invention.

[0006] In one embodiment of the present disclosure, an automated injector device for delivering a drug is disclosed. The automated injector device comprises a syringe assembly having a needle adapted to release a drug from the syringe assembly. The syringe assembly comprises a barrel adapted to hold the drug and connect to the needle. The flow of the drug is directed out of the barrel through the needle. The syringe assembly comprises a plunger positioned coaxially with the barrel and adapted to reciprocate within the barrel to release the drug from the barrel. Furthermore, the syringe assembly comprises a locking member adapted to engage with the plunger and hold the plunger in a certain position relative to the barrel. The position of the plunger relative to the barrel is adapted to be adjusted to vary the amount of drug released from the barrel. The position of the plunger is adjusted by engaging the locking member with the plunger at one of a plurality of positions along the length of the plunger.

[0007] To further clarify the advantages and features of the present invention, a more specific description of the invention will be given with reference to specific embodiments shown in the accompanying drawings. It should be understood that these drawings only show typical embodiments of the invention and should therefore not be considered limiting its scope. The present invention will be described and explained in more specific and detail with reference to the accompanying drawings. [Brief explanation of the drawing]

[0008] These and other features, aspects, and advantages of the present invention will be better understood by reading the following detailed description with reference to the attached drawings, where similar letters represent similar parts throughout the drawings: [Figure 1] Figure 1 illustrates the steps involved in the implementation of an automated injector device and a drug delivery device according to one embodiment of the present disclosure; [Figure 2a] Figure 2a shows a perspective view of an automatic injector device according to one embodiment of the present disclosure; [Figure 2b] Figure 2b shows an exploded view of an automatic injector device according to one embodiment of the present disclosure; [Figure 3a] Figure 3a shows a cross-sectional view of an automatic injector device according to one embodiment of the present disclosure; [Figure 3b] Figure 3b shows a cross-sectional view of an automatic injector device according to one embodiment of the present disclosure; [Figure 4] Figure 4 shows a perspective view of a plunger of an automatic injector device according to one embodiment of the present disclosure; [Figures 5a-5c] Figures 5a-5c illustrate the operation of an automated injector device for drug delivery according to one embodiment of the present disclosure; and, [Figure 6] Figure 6 shows an enlarged cross-sectional view of a portion A of the automatic injector device shown in Figure 5c, according to one embodiment of the present disclosure.

[0009] Furthermore, those skilled in the art will understand that elements in the drawings are illustrated for simplification and may not necessarily be drawn to a specific scale. For example, flowcharts illustrate methods with respect to the most prominent steps involved to help understand aspects of the invention. Moreover, with respect to the structure of a device, one or more components of the device may be represented in the drawings by conventional symbols, and the drawings may show only certain details relevant to understanding embodiments of the invention so as not to obscure the drawings with details that would be readily apparent to those skilled in the art who benefit from the description herein.

[0010] Detailed description of the drawing For the purpose of facilitating an understanding of the principles of the present invention, embodiments shown in the drawings will be referenced, and specific language will be used to describe them. Nevertheless, it will be understood that this is not intended to limit the scope of the invention. Such changes and further modifications in the illustrated systems, as well as such further applications of the principles of the invention illustrated therein, are intended to be contemplated as would normally be conceived by those skilled in the art to which the invention relates. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the invention belongs. The systems, methods, and examples provided herein are for illustrative purposes only and are not intended to limit the scope.

[0011] As used herein, the term “part” is defined as “none, one, more than one, or all.” Thus, the terms “none,” “one,” “multiple,” “multiple but not all,” or “all” all fall under the definition of “part.” The term “some embodiments” may refer to the absence of embodiments, one embodiment, several embodiments, or all embodiments. Thus, the term “some embodiments” is defined as meaning “no embodiments, one embodiment, two or more embodiments, or all embodiments.”

[0012] The terms and structures used herein are for the purpose of describing, teaching, and illustrating certain embodiments and their specific features and elements, and are not intended to limit, restrict, or diminish the spirit and scope of the claims or their equivalents.

[0013] More specifically, any term used herein, including but not limited to “include,” “contain,” “have,” “constitute,” and their grammatical variations, does not, unless otherwise specified, specify a precise limitation or restriction, nor does it preclude the possibility of adding one or more features or elements, nor should it be considered to preclude the possibility of deleting one or more of the listed features and elements unless otherwise stated with the limiting phrase “must include” or “must contain.” Regardless of whether a particular feature or element is limited to being used only once, it may still be referred to as "one or more features," "one or more elements," or "at least one feature" or "at least one element." Furthermore, the use of the terms "one or more" or "at least one" feature or element does not preclude the absence of any of those features or elements unless otherwise specified by restrictive words such as "there must be one or more..." or "there must be one or more elements." Unless otherwise defined, all terms used herein, in particular technical and / or scientific terms, should be construed to have the same meaning as that generally understood by those skilled in the art.

[0014] This specification refers to several "embodiments." It should be understood that embodiments are examples of possible implementations of any features and / or elements presented in the appended claims. Some embodiments have been described for the purpose of revealing one or more potential ways in which particular features and / or elements of the appended claims satisfy the requirements of uniqueness, usefulness, and non-obviousness.

[0015] The use of phrases and / or terms such as “first embodiment,” “further embodiment,” “alternative embodiment,” “one embodiment,” “embodiment,” “multiple embodiments,” “several embodiments,” “other embodiments,” “further embodiments,” “even further embodiments,” “additional embodiments,” or variations thereof, does not necessarily refer to the same embodiment. Unless otherwise specified, one or more specific features and / or elements described in relation to one or more embodiments may be found in one embodiment, in two or more embodiments, in all embodiments, or not in any embodiment.

[0016] One or more features and / or elements may be described herein in the context of a single embodiment only, or alternatively in the context of multiple embodiments, or even more alternatively in the context of all embodiments, but features and / or elements may instead be provided individually or in appropriate combinations, or not provided at all. Conversely, any features and / or elements described in the context of a separate embodiment may alternatively be realized as coexisting in the context of a single embodiment.

[0017] All specific details described herein are used in the context of certain embodiments and should not necessarily be construed as limiting factors to the appended claims. The appended claims and their legal equivalents may be realized in the context of embodiments other than those used as illustrative in the following description. Embodiments of the present invention will be described in detail below with reference to the attached drawings.

[0018] Figure 1 shows an auto-injector device 100 according to an embodiment of the present disclosure, and steps involved in the implementation of the auto-injector device 100 for delivering a medicament. In one embodiment, the auto-injector device 100 may be used to deliver a medicament (alternatively referred to as a drug) to a patient. The auto-injector device 100 may include a proximal end 102 and a distal end 104. Further, the auto-injector device 100 may include a cap 106 removably attached to the distal end 104 of the auto-injector device 100. The cap 106 may be provided to protect the needle of the auto-injector device 100 and limit the entry of contaminants into the auto-injector device 100.

[0019] To implement the auto-injector device 100 for the medicament, referring to FIG. 1, at step 108, the cap 106 of the auto-injector device 100 may be removed to deliver the medicament to the patient. Subsequently, at step 110, the distal end 104 of the auto-injector device 100 may be placed on an injection site corresponding to the subcutaneous (sub-Q) region to deliver the medicament to the patient. When the auto-injector device 100 is placed at the site, the auto-injector device 100 may be pushed in the direction towards the injection site and held for a predetermined time to deliver the medicament to the patient through the site. Subsequently, at step 112, the auto-injector device 100 may be removed from the injection site and discarded into a sharp collector. Details of the structure and operation of the auto-injector device 100 will be described in detail in subsequent sections of the present disclosure.

[0020] Figure 2a shows a perspective view of an auto-injector device according to an embodiment of the present disclosure. Figure 2b shows an exploded view of the auto-injector device 100 according to an embodiment of the present disclosure. Figures 3a and 3b show cross-sectional views of the auto-injector device 100 according to an embodiment of the present disclosure. Referring to Figures 2a, 2b, and 3a, in one embodiment, the auto-injector device 100 may include a first body member 202 and a second body member 204. The first body member 202 and the second body member 204 may be adapted to be coupled to each other to define a housing 205 for accommodating various sub-components of the auto-injector device 100. In one embodiment, the first body member 202 and the second body member 204 may be coupled to each other via a snap lock without departing from the scope of the present disclosure.

[0021] Furthermore, the auto-injector device 100 may include a syringe assembly 206, a prefilled syringe (PFS) holder 208, a needle guard 210, a needle guard spring 212, a locking member 214, a plunger 216, a plunger spring 218, and a spring release arm 220. In one embodiment, the syringe assembly 206 may include, but is not limited to, a needle 222 and a barrel 224 adapted to be coupled to the needle 222. The barrel 224 may be adapted to hold a drug. The barrel 224 may include a front portion and a rear portion distal to the front portion. The front portion may be adapted to be coupled to the needle 222, and the rear portion may be adapted to movably receive the plunger 216.

[0022] Furthermore, the needle 222 may be fitted to release the drug from the syringe assembly 206. The needle 222 may be fitted to connect to the front portion of the barrel 224 so that the flow of the drug may be directed out of the barrel 224 through the needle 222 during the operation of the automatic injector device 100. Furthermore, the PFS holder 208 may be fitted to hold the syringe assembly 206 within the housing 205 of the automatic injector device 100.

[0023] In one embodiment, the needle guard 210 may be adapted to house the PFS holder 208 together with the syringe assembly 206 within the automatic injector device 100. The needle guard 210 may include a proximal end 210-1 and a distal end 210-2. Furthermore, a needle guard spring 212 may be adapted to be connected to the needle guard 210. The needle guard spring 212 may be provided to allow elastic movement of the needle guard 210 in the direction along the axis X-X' of the automatic injector device 100 during operation of the automatic injector device 100.

[0024] Furthermore, the spring release arm 220 may be located at the proximal end 102 of the automatic injector device 100. In one embodiment, the spring release arm 220 may be adapted to be connected to a second body member 204. The spring release arm 220 may be adapted to support the plunger 216 and plunger spring 218 within the automatic injector device 100. The plunger 216 may be located coaxially with respect to the barrel 224. The plunger 216 may be adapted to reciprocate within the barrel 224 to release the drug and to draw the drug into the barrel 224. The plunger 216 may be adapted to move along the axis X-X' of the automatic injector device 100. The plunger 216 may be adapted to reciprocate within the barrel 224 of the syringe assembly 206 to release the drug from the syringe assembly 206 and to draw the drug into the barrel 224.

[0025] Furthermore, a plunger spring 218 may be provided to enable the elastic movement of the plunger 216 within the barrel 224 in a direction along axis X-X'. In particular, during the operation of the automatic injector device 100, the plunger spring 218 may be adapted to elastically push the plunger 216 within the barrel 224 to release the drug from the barrel 224 of the syringe assembly 206. The plunger spring 218 may be adapted to be compressed between the head portion of the plunger 216 and the locking member 214.

[0026] Figure 4 shows a perspective view of a plunger 216 of an automatic injector device 100 according to one embodiment of the present disclosure. In one embodiment, a locking member 214 may be fitted to engage with the plunger 216 to hold the plunger in a certain position relative to the barrel 224. Furthermore, the locking member 214 may be fitted to hold the spring release arm 220 in a locked position to ensure engagement of the spring release arm 220 with the plunger 216. In one embodiment, the locking member 214 may be fitted to surround at least a portion of the spring release arm 220 to prevent the spring release arm 220 from bending radially outward relative to the plunger 216, thereby ensuring engagement of the plunger 216 with the spring release arm 220.

[0027] Referring to Figures 3a, 3b, and 4, the plunger 216 may include an engagement portion 402 extending along the length L of the plunger 216. In one embodiment, the engagement portion 402 may be embodied as one of a helical groove and a circular groove, without departing from the scope of the present disclosure. The locking member 214 may be adapted to engage with the engagement portion 402 of the plunger 216 to hold the plunger 216 in position within the automatic injector device 100. In particular, the locking member 214 may engage at one of a plurality of positions within the engagement portion 402 along the length L of the plunger 216.

[0028] The position of the plunger 216 relative to the barrel 224 may be adapted to adjust to vary the amount of drug released from the barrel 224. The position of the plunger 216 may be adjusted by engaging a locking member 214 with the plunger at one of a plurality of positions along the length L of the plunger 216. In one embodiment, the locking member 214 may include locking teeth 302 adapted to engage with the engagement portion 402 of the plunger 216. The locking member 214 may be movable between an engaged position and a released position.

[0029] In one embodiment, the needle guard 210 may be adapted to move the locking member 214 from an engaged position to a released position. In the engaged position, the locking teeth 302 may engage with the engaging portion 402 to hold the plunger 216 at a position away from the distal end 104 of the auto injector device 100. In such a position, the plunger spring 218 may be compressed between the head portion of the plunger 216 and the locking member 214. Furthermore, in the released position, the needle guard 210 may move the locking member 214 toward the proximal end 102 of the auto injector device 100. Due to such movement of the locking member 214, the locking teeth 302 may be released from the engaging portion 402 of the plunger 216. Subsequently, the plunger spring 218 may push the plunger 216 in the barrel 224 toward the distal end 104 of the auto injector device 100 to release the drug from the syringe assembly 206.

[0030] As described above, the position of the plunger 216 relative to the barrel 224 in the automatic injector device 100 may be adjustable to deliver different amounts of drug from the automatic injector device 100. Referring to Figures 3b and 4, in one example, the locking member 214 may engage with the engagement portion 402 at a distance X1 with respect to the length L of the plunger 216. In such a case, the plunger 216 may be held at a certain position P1 relative to the front portion 210-1 of the barrel 224 in the automatic injector device 100.

[0031] For such a position of the plunger 216, the barrel 224 may hold a volume V1, i.e., the maximum volume of drug to be dispensed through the needle 222 during the operation of the automatic injector device 100. In another example, the locking member 214 may engage with the engaging portion 402 at a distance X2 with respect to the length L of the plunger 216. In such a case, the plunger 216 may be held at a position P2 with respect to the front portion 210-1 of the barrel 224 in the automatic injector device 100. For such a position of the plunger 216, the barrel 224 may hold a volume V2 of drug to be dispensed through the needle 222.

[0032] However, in the illustrated embodiment, the operation of the plunger 216 and the locking member 214 is described in relation to positions P1 and P2 of the plunger 216 within the automatic injector device 100. As will be understood by those skilled in the art, without departing from the scope of the disclosure, the plunger 216 may be locked in multiple positions by the locking member 214 to change the amount of drug delivered from the automatic injector device 100 as needed.

[0033] Figures 5a–5c illustrate the operation of an automated injector device 100 for drug delivery according to one embodiment of the present disclosure. Figure 6 shows an enlarged cross-sectional view of portion A of the automated injector device 100 shown in Figure 5c, according to one embodiment of the present disclosure. Firstly, in order to deliver drug to the patient's sub-cue area through the automated injector device 100, the cap 106 may be removed from the distal end 104 of the automated injector device 100 to expose the needle 222 of the syringe assembly 206.

[0034] Furthermore, referring to Figure 5b, the distal end 104 of the automated injector device 100 may be positioned at the injection site, i.e., the skin, corresponding to the patient's sub-cue area. In one embodiment, the injection site may be selected based on various parameters such as prescription, type of drug, and amount of drug to be injected, without departing from the scope of the present disclosure. Subsequently, the automated injector device 100 may be pressed against the skin such that the needle guard 210 is pressed against the skin, resulting in the needle guard 210 moving toward the proximal end 102 of the automated injector device 100. Due to such movement of the needle guard 210, the needle 222 may be inserted into the patient's sub-cue area to deliver the drug. Furthermore, once the drug is injected, the automated injector device 100 may be moved away from the skin, resulting in the movement of the needle guard 210 covering the needle 222 of the automated injector device 100. This effectively eliminates the potential injury that could occur due to the needle being exposed when the automated injector device 100 is withdrawn from the injection site.

[0035] Referring to Figures 5c and 6, the movement of the needle guard 210 may push the locking member 214 toward the proximal end 102 of the auto-injector device 100. Such movement of the locking member 214 may result in the release of the locking teeth 302 from the engaging portion 402 of the plunger 216. In particular, the locking teeth 302 may move laterally away from the engaging portion 402, thereby unlocking the movement of the plunger 216 under the elastic force of the plunger spring 218. Subsequently, the plunger 216 may move toward the distal end 104 of the auto-injector device 100 within the barrel 224 under the elastic force of the plunger spring 218. The plunger 216 may push the drug held within the barrel 224 to deliver the drug to the patient's sub-cue area through the needle 222 of the syringe assembly 206.

[0036] In one embodiment, a rubber stopper (not shown) may be attached to the plunger 216 and adapted to move with the plunger 216 within the barrel 224 to release the drug held within the barrel 224 of the syringe assembly 206. The rubber stopper may be adapted to be inserted into the barrel 224 in such a way that the rubber stopper may function as a sealing member to prevent the drug from flowing out from one end of the barrel 224. The rubber stopper may move with the plunger 216 to release the drug from the barrel 224 through a needle 222 located at the other end of the barrel 224.

[0037] As can be seen, the automated injector device 100 of this disclosure includes a locking member 214 adapted to lock a plunger 216 at different positions for administering different amounts of drug through the automated injector device 100. The plunger 216 may include an engaging portion 402 extending along the length L of the plunger 216. The locking member 214 may engage with the engaging portion 402 to hold the plunger 216 in a pre-loaded position for releasing drug from the syringe assembly 206. The locking member 214 may engage with the engaging portion 402 at different positions along the length L of the plunger 216 to vary the amount of drug administered through the automated injector device 100.

[0038] Therefore, the automated injector device 100 can be reused for different types and doses of drugs without modifying the subcomponents of the automated injector device 100. In particular, this may reduce the need to manufacture different subcomponents of the automated injector device 100 for administering different types and doses of drugs. Furthermore, this substantially reduces the overall manufacturing cost of the automated injector device 100. Thus, the automated injector device 100 of this disclosure is flexible in implementation, compact, cost-effective, convenient, and has a wide range of applications.

[0039] The automated injector device 100 described herein may be used to deliver a variety of therapeutic compounds, including but not limited to drugs and biological agents, antibodies, antisense agents, RNA interference agents, gene therapies, primary and embryonic stem cells, vaccines, and combinations thereof. For example, the embodiments described herein can be used in combination with known monoclonal antibodies, including but not limited to:

[0040] Abcisimab, Abituzumab, Abrilumab, Actoxumab, Adalimumab, Adecatumumab, Aducanumab, Afasevikumab, Afelimomab, Afutuzumab, Alacizumab pegol, ALD518, ALD403, Alemtuzumab, Alirocumab, Altumomab Pentetate pentetate), Amatuximab, AMG334, Anatumomab mafenatox, Anetumab ravtansine, Anifrolumab, Anrukinzumab, Apolizumab, Arcitumomab, Ascrinvacumab, Aselizumab, Atezolizumab, Atinumab, Atlizumab, Atorolimumab, Avelumab, Bapineuzumab, Basil iximab), Bavituximab, Bectumomab, Begelomab, Belimumab, Benralizumab, Bertilimumab, Besilesomab, Bevacizumab, Bezlotoxumab, Biciromab, Bimagrumab, Bimekizumab, Bivatuzumab meltansinemertansine), bleserumab, blinatumomab, blontuvetmab, brosozumab, bococizumab, brazikumab, brentuximab vedotin, briakinumab, brodalumab, brolucizumab, brontictuzumab, burosumab, cabilalizumab, canakinumab, cantuzumab mertansine, cantuzumab labtansine ravtansine), caplacizumab, capromab pendetide, casirivimab, carlumab, carotuximab, catumakisomab, cBR96-doxorubicin immunoconjugate, cedelizumab, cergutuzumab amunaleukin, certolizumab pegol, cetuximab, citatuzumab vogatox bogatox), cixutumumab, clazakizumab, clenoliximab, clivatuzumab tetraxetan, codrituzumab, coltuximab ravtansine, conatumumab, concizumab, CR6261, crenezumab, clotedumab,

[0041] Dacetuzumab, Daclizumab, Dalotuzumab, Dapirolizumab pegol, Daratumumab, Detrekumab, Demcizumab, Denintuzumab mafodotin, Denosumab, Depatuxizumab mafodotin, Derlotuximab biotin), Detumomab, Dinutuximab, Diridavumab, Domagrozumab, Dorlimomab aritox, Drozitumab, Duligotumab, Dupilumab, Durvalumab, Dusigitumab, Ecromeximab, Eculizumab, Edobacomab, Edrecolomab, Efalizumab ), Efungumab, Eldelumab, Elgemtumab, Elotuzumab, Elsilimomab, Emactuzumab, Emibetuzumab, Emicizumab, Enavatuzumab, Enfortumab vedotin, Enlimomab pegol, Enoblituzumab, Enokizumab, Enoticumab, Ensituximab, Epitumomabcituxetan), epratuzumab, erenumab, erlizumab, ertumaxomab, etaracizumab, etrolizumab, evinacumab, evolocumab, exbivirumab, fanolesomab, faralimomab, farletuzumab, facinumab, FBTA05, felvizumab, fezakinumab, fibatuzumab, f Ficlatuzumab, Figitumumab, Firivumab, Flambotumab, Fletikumab, Fontolizumab, Foralumab, Foravirumab, Fresolimumab, Fulranumab, Futuximab, Galcanezumab, Galiximab, Ganitumab, Gantenerumab, Gavilimomab, Gemtuzumab ozogamicin ozogamicin), gevokizumab, girentuximab, glembatumumab vedotin, golimumab, gomiliximab, guselkumab,

[0042] Ibalizumab, Ibritumomab tiuxetan, Icrucumab, Idarucizumab, Igovomab, IMA-638, IMA-362, Imalumab, Imciromab, Imdevimab, Imgatuzumab, Inclacumab, Indatuximab ravtansine, Indasatumab vedotin Vedotin, Inebilizumab, Infliximab, Inolimomab, Inotuzumab ozogamicin ozogamicin), intetumumab, ipilimumab, iratumumab, isatuximab, itolizumab, isekizumab, keriximab, labetuzumab, lambrolizumab, lampalizumab, lanadelumab, landogrozumab, laprituximab emtansine emtansine), LBR-101 / PF0442g7429, lebrikizumab, lemalesomab, lensalizumab, lensilumab, lerdelimumab, lexatumumab, livivirumab, lifastuzumab vedotin, ligerizumab, lilotomab / satetraxetansatetraxetan), lintuzumab, lirilumab, lodelcizumab, lokivetmab, lorvotuzumab mertansine, lucatumumab, lurizumab pegol pegol), Lumiliximab, Ramretuzumab, LY2951742, Mapatumumab, Margetuximab, Maslimomab, Matuzumab, Mavrilimumab, Mepolizumab, Metelimumab, Miratuzumab, Minretumomab, Mirvetuximab / Sorabtansine soravtansine), Mitumomab, Mogamulizumab, Monalizumab, Morolimmumab, Motavizumab, Moxetumomab pasudotox, Muromonab-CD3, Nacolomab tafenatox, Namilumab, Naptumomab estafenatox, Naratuximab emtansine), narnatumab, natalizumab, navicixizumab, navivumab, nevacumab, necitumumab, nemolizumab, nererimomab, nesvacumab, nimotuzumab, nivolumab, nofetumomab / merpentanmerpentan)、

[0043] Obintoxaximab, Obinutuzumab, Ocaratuzumab, Ocrelizumab, Odulimomab, Ofatumumab, Olaratumab, Olokizumab, Omalizumab, Onartuzumab, Ontuxizumab, Opicinumab, Oportuzumab monatox Monatox), Oregovomab, Orticumab, Otelixizumab, Otlertuzumab, Oxelumab, Ozanezumab, Ozoralizumab, Pagibaximab, Palivizumab, Pamrevlumab, Panitumumab, Pankomab, Panobac umab), Parsatuzumab, Pascolizumab, Pasotuxizumab, Pateclizumab, Patritumab, Pembrolizumab, Pembrolizumab, Pemtumomab, Perakizumab, Pertuzumab, Pexelizumab, Pidilizumab, Pinatuzumab Vedotin Polatuzumab vedotin, Pintumomab, Placulumab, Plozalizumab, Pogalizumab, Polatuzumab vedotinVedotin, Ponezumab, Prezalizumab, Priliximab, Pritoxaximab, Pritumumab, PRO140, Quilizumab, Racotumomab, Radretumab, Rafivirumab, Ralpancizu mab), Ramucirumab, Ranibizumab, Raxibacumab, Refanezumab, Regavirumab, Reslizumab, Rilotumumab, Rinucumab, Risankizumab, Rituximab, Rivabazumab pegol pegol), Robatumumab, Rolledumab, Romosozumab, Rontalizumab, Rovalpituzumab tesirine, Robelizumab, Ruplizumab, Sacituzumab govitecan, Samalizumab, Sapelizumab, Sarilumab, Satumomab pendetidependetide), Secukinumab, Seribantumab, Setoxaximab, Sevirumab, SGN-CD19A, SGN-CD33A, Sibrotuzumab, Sifalimumab, Siltuximab, Simtuzumab, Siplizumab, Sirukumab, Sofituzumab vedotin Vedotin, solanezumab, solitomab, sonepcizumab, sontuzumab, stamulumab, sulesomab, suvizumab,

[0044] Tavarmab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tamtuvetmab, Tanezumab, Taplitumomab paptox, Tarextumab, Tefibazumab, Telimomab aritox), tenatumomab, teneliximab, teplizumab, teprotumumab, tesidolumab, tetulomab, tezepelumab, TGN1412, ticilimumab, tigatuzumab, tildrakizumab, timolumab, tisotumab vedotin Vedotin, TNX-650, Tocilizumab, Toralizumab, Tosatoxumab, Tositumomab, Tovetumab, Tralokinumab, Trastuzumab, Trastuzumab emtansine, TRBS07, Tregalizumab, Tremelimumab, Trevogrumab, Tucotuzumab celmoleukin), tuvirumab, ublituximab, urocuplumab, urelumab, urtoxazumab, ustekinumab, utomilumab, vadastuximab tarillintalirine), Vandortuzumab vedotin, Vantictumab, Vanucizumab, Vapaliximab, Varlilumab, Vatelizumab, Vedolizumab, Veltuzumab, Vepalimomab, Vesencumab, Visilizumab, Vobarilizumab, Volociximab, Vorsetuzumab mafodotin, botumumab, xentuzumab, zalutumumab, zanolimumab, zatuximab, ziralimumab, and zolimomab aritox, or a combination thereof.

[0045] While certain terms are used to describe the subject matter, no limitation arising therefrom is intended. As will be apparent to those skilled in the art, various operational modifications may be made to the methods in order to implement the inventive concepts taught herein. The drawings and the preceding description provide examples of embodiments. Those skilled in the art will understand that one or more of the described elements may be combined into a single functional element. Alternatively, certain elements may be divided into multiple functional elements. Elements of one embodiment may be added to another embodiment.

Claims

1. An automatic injector device (100): Syringe assembly (206): A needle (222) adapted to release the drug from a syringe assembly (206); and A barrel (224) is fitted to hold the drug and to connect to a needle (222), and the flow of the drug is directed out of the barrel through the needle (222). including, The syringe assembly (206), A plunger (216) positioned coaxially with the barrel (224) and adapted to reciprocate within the barrel (224) to release the drug; A locking member (214) is fitted to engage with the plunger (216) and holds the plunger in a certain position relative to the barrel (224); A needle guard (210) configured to move a locking member (214) toward the proximal end (102) of an automatic injector device (100); and A spring release arm (220) is located at the proximal end (102) of an automatic injector device (100) and is configured to support a plunger (216) and a plunger spring (218), wherein a locking member (214) is fitted to hold the spring release arm (220) in a locked position and to ensure engagement of the spring release arm (220) with the plunger (216). Includes, The position of the plunger (216) relative to the barrel (224) is adapted to be adjusted to change the amount of agent released from the barrel (224), and the position of the plunger (216) is adjusted by engaging the locking member (214) with the plunger (216) at one of several positions along the length (L) of the plunger (216). The needle guard (210) is adapted to move the locking member (214) from the engaged position to the released position. The aforementioned automatic injector device.

2. The automatic injector device (100) according to claim 1, further comprising a first main body member (202) and a second main body member (204), wherein the first main body member (202) and the second main body member (204) are adapted to be connected to each other so as to define a housing (205) therein.

3. An automated injector device (100) according to claim 1 or 2, further comprising a pre-filled syringe (PFS) holder (208) adapted to hold a syringe assembly (206) within a housing (205).

4. The automatic injector device (100) according to claim 1, wherein the plunger (216) includes an engaging portion (402) that extends along the length (L) of the plunger (216), and the locking member (214) engages at one of a plurality of positions on the engaging portion (402) along the length (L).

5. The automatic injector device (100) according to claim 4, wherein the locking member (214) includes locking teeth (302) adapted to engage with the engaging portion (402) of the plunger (216).

6. The automatic injector device (100) according to claim 1 further includes a needle guard spring (212) adapted to be connected to a needle guard (210), wherein the needle guard spring (212) is adapted to allow elastic movement of the needle guard (210).

7. In the engagement position, the locking teeth (302) engage with the engagement portion (402) to hold the plunger (216) away from the distal end (104) of the automatic injector device (100); In the release position, the needle guard (210) moves the locking member (214) toward the proximal end (102) of the automatic injector device (100) so as to release the locking teeth (302) from the engagement portion (402). The automatic injector device (100) according to claim 6.

8. The present invention further includes a plunger spring (218) fitted to be compressed between the head portion of the plunger (216) and the locking member (214), and fitted to cause the plunger spring (218) to elastically push the plunger (216) within the barrel (224) to release the drug from the barrel (224). The automatic injector device (100) according to claim 1.

Images